Home » News » Clinical Intelligence » New patient adherence tech tests the limits

New patient adherence tech tests the limits

Monday, November 27, 2017

With the FDA’s recent approval of Abilify MyCite, a “digital pill” that can indicate whether a patient has taken his or her medication, physicians may finally have an effective way of attacking the problem of medication nonadherence. Abilify MyCite is a drug-device combina-tion product that consists of Otsuka Pharmaceutical’s oral Abilify (aripiprazole) tablets that have been embedded with an ingestible biosensor developed by Proteus Digital Health.

Former Eli Lilly Exec, Alex Azar, named primary nominee for Secretary of HHS

President Trump has named Alex Azar, a former executive at Eli Lilly, as a leading nominee for the role of Secretary of Health and Human Services (HHS). If selected, Azar will replace the former HHS Secretary Tom Price, who left the position after news of his misuse of travel funds came to light. Key advice from conservative thinkers and health policy insiders helped form President Trump’s decision to nominate the now-resigned Eli Lilly executive.


To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!